RPG Life Sciences Limited demonstrated strong financial performance in Q1 FY27, with a standalone net profit of ₹30.6 crore, up 16.35% from ₹26.3 crore in the same quarter last year. This growth was fueled by a 15.8% increase in revenue from operations to ₹195.7 crore and a 17.9% rise in EBITDA to ₹48.0 crore, improving margins to 24.5%. The Domestic Formulations segment outperformed the broader Indian Pharma Market, growing 14.8%, while the API business rebounded significantly with a 35.6% increase, reflecting restored operational efficiency. RPG Life Sciences has secured a place among the Top 50 Indian pharmaceutical companies as of June 2026, further strengthening its market position.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.sahi.com/news/rpg-life-sciences-q1-standalone-net-profit-rises-to-30-6-crore-vs-26-3-crore-3748-PE1_COR
